Your browser doesn't support javascript.
loading
Effects of Curcumin C3 Complex® on Physical Function in Moderately Functioning Older Adults with Low-Grade Inflammation - A Pilot Trial.
Mankowski, R T; Sibille, K T; Leeuwenburgh, C; Lin, Y; Hsu, F-C; Qiu, P; Sandesara, B; Anton, S D.
Affiliation
  • Mankowski RT; Robert T. Mankowski, PhD, Department of Aging and Geriatric Research, University of Florida, 2004 Mowry Road, Gainesville, FL, 32611, United States. Phone: +1 (352) 294-5055, Fax: +1 (352) 294-5836, E-mail: r.mankowski@ufl.edu.
J Frailty Aging ; 12(2): 143-149, 2023.
Article in En | MEDLINE | ID: mdl-36946712
ABSTRACT

BACKGROUND:

Natural dietary compounds that can modulate the inflammation process have the potential to improve physical function through a number of biological pathways, and thus may represent an alternative approach to avert functional decline compared to more time-burdening lifestyle interventions. In this pilot trial, we tested the feasibility and explored the effect of a nutritional compound, Curcumin C3 Complex® for improving physical function and muscle strength in moderately functioning older adults with low-grade inflammation.

METHODS:

Moderately functioning (short physical performance battery, SPPB <10) and sedentary older adults (>65 years) with low-grade systemic inflammation (c-reactive protein >1mg/dL) were randomized to receive Curcumin C3 Complex® (n=9) (1000mg/day) or placebo (n=8) groups for 12 weeks. All participants (age range 66-94 years, 8 females and 9 males) underwent functional testing (SPPB and walking speed by the 400-meter walk test) and lower-limb strength (knee flexion and extension peak torque by the Biodex test) at baseline and 12 weeks. Venous blood was collected at baseline, 4, 8 and 12 weeks for safety blood chemistry analyses and biomarkers of inflammation.

RESULTS:

A total of 17 participants were randomized and completed the study. Adherence was high (> 90%) and there were no adverse events reported or abnormal blood chemistries reported. Based on effect sizes, participants in the Curcumin C3 Complex® group demonstrated large effect sizes in the SPPB (Cohen's effect size d=0.75) and measures of knee extension (d=0.69) and flexion peak torque (d=0.82). Effect sizes for galectin-3 (d=-0.31) (larger decrease) and interleukin-6 (d=0.38) (smaller increase) were small in the Curcumin C3 Complex® group compared to placebo.

CONCLUSION:

This pilot trial suggests that there were no difficulties with recruitment, adherence and safety specific to the study protocol. Preliminary findings warrant a Phase IIb clinical trial to test the effect of Curcumin C3 Complex® on physical function and muscle strength in older adults at risk for mobility disability.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Curcumin Type of study: Clinical_trials / Guideline Limits: Aged / Aged80 / Female / Humans / Male Language: En Journal: J Frailty Aging Year: 2023 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Curcumin Type of study: Clinical_trials / Guideline Limits: Aged / Aged80 / Female / Humans / Male Language: En Journal: J Frailty Aging Year: 2023 Document type: Article